The expression of bcl-2 and MDR in renal cell carcinoma
10.3969/j.issn.1001-1420.2001.02.011
- VernacularTitle:bcl-2及MDR-1基因产物在肾癌组织中的表达及其意义
- Author:
Xudong YAO
1
;
Yaguang YUAN
;
Yazheng ZHANG
;
Qingnuan SUN
;
Tengxiang MA
Author Information
1. the First Affiliated Hospital Innermongolia Medical College
- From:
Journal of Clinical Urology
2001;16(2):77-79
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study bcl-2 and MDR expressions in renal cell carcinoma and to evaluate its clinical significance.Methods:blc-2 and MDR expression were studied by immunohistochemical technique in 48 specimens of renal cell carcinoma tissues and in 10 normal renal tissues and their clinical significance was analyzed.Results:The positive rate of expression of bcl-2 in the renal cell carcinoma tissue was 77.1%, while it was 40.0% in the normal renal tissue(P＜0.05). However, it was not related to the tumor grade and tumor stage(P＞0.05). On the other hand, There was a positive expression of MDR1 in renal cell carcinoma and normal renal tissue. MDR1 was positively related to tumor cell type(P＜0.05). Compared with the other types of renal cell carcinoma. The granular existed higher expression. Both have no relationship with prognosis.Conclusions: bcl-2 Protein is overexpressed in the majority of renal cell carcinomas. The overexpression of bcl-2 may have a role in tumorigenesis. MDR1, an established predictor for chemo-resistance, however, has no significant correlation with bcl-1. The multidrug resistant of renal cell cancer is probably induced by double-functions of bcl and MDR1.
